Terms: = Skin cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Treatment
27 results:
1. A locally advanced colon cancer patient with Muir-Torre syndrome obtains durable response to neoadjuvant and adjuvant immunotherapy.
Guo Z; Cai Y; Yin W; Huang J
Tumori; 2023 Dec; 109(6):NP27-NP31. PubMed ID: 37880978
[TBL] [Abstract] [Full Text] [Related]
2. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
Front Immunol; 2021; 12():629519. PubMed ID: 33746966
[TBL] [Abstract] [Full Text] [Related]
3. Mismatch repair protein loss in cutaneous head and neck squamous cell carcinoma.
Vasan K; Anand S; Satgunaseelan L; Asher R; Low H; Palme CE; Lee JH; Clark JR; Gupta R
J Surg Oncol; 2020 Dec; 122(8):1755-1760. PubMed ID: 32926758
[TBL] [Abstract] [Full Text] [Related]
4. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract] [Full Text] [Related]
5. Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
Dogan A; Kern P; Schultheis B; Häusler G; Rezniczek GA; Tempfer CB
BMC Cancer; 2018 Apr; 18(1):463. PubMed ID: 29690864
[TBL] [Abstract] [Full Text] [Related]
6. Cutaneous Metastasis of Adenocarcinoma of the Ampulla of Vater.
Fernandez-Flores A; Cassarino DS
Am J Dermatopathol; 2018 Oct; 40(10):758-761. PubMed ID: 29672360
[TBL] [Abstract] [Full Text] [Related]
7. Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability.
Santamaría PG; Floristán A; Fontanals-Cirera B; Vázquez-Naharro A; Santos V; Morales S; Yuste L; Peinado H; García-Gómez A; Portillo F; Hernando E; Cano A
Cell Death Differ; 2018 May; 25(5):935-950. PubMed ID: 29229995
[TBL] [Abstract] [Full Text] [Related]
8. Sebaceous Carcinoma Treated With Mohs Micrographic Surgery.
Brady KL; Hurst EA
Dermatol Surg; 2017 Feb; 43(2):281-286. PubMed ID: 28165350
[TBL] [Abstract] [Full Text] [Related]
9. Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
Sharma G; Lian CG; Lin WM; Amin-Mansour A; Jané-Valbuena J; Garraway L; Bao W; Yoon CH; Ibrahim N
J Cutan Pathol; 2016 Oct; 43(10):884-91. PubMed ID: 27251777
[TBL] [Abstract] [Full Text] [Related]
10. [Challenges for Urologists in the Care of Patients with Lynch Syndrome: Example of A Patient with Muir-Torre Syndrome, A Subtype of Lynch Syndrome].
Löhmann C; Kächele V; Martinschek A; Sparwasser C
Aktuelle Urol; 2016 Apr; 47(2):144-7. PubMed ID: 26509248
[TBL] [Abstract] [Full Text] [Related]
11. MiR-21: an environmental driver of malignant melanoma?
Melnik BC
J Transl Med; 2015 Jun; 13():202. PubMed ID: 26116372
[TBL] [Abstract] [Full Text] [Related]
12. Resolution of Benign and Malignant Sebaceous Neoplasms, in a Renal Transplant Patient Treated With Everolimus.
Donati M; Paolino G; Muscardin L; Panetta C; Donati P
Exp Clin Transplant; 2017 Feb; 15(1):100-102. PubMed ID: 25924010
[TBL] [Abstract] [Full Text] [Related]
13. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Roos WP; Quiros S; Krumm A; Merz S; Switzeny OJ; Christmann M; Loquai C; Kaina B
Oncotarget; 2014 Dec; 5(24):12607-20. PubMed ID: 25557167
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD).
Wimmer K; Kratz CP; Vasen HF; Caron O; Colas C; Entz-Werle N; Gerdes AM; Goldberg Y; Ilencikova D; Muleris M; Duval A; Lavoine N; Ruiz-Ponte C; Slavc I; Burkhardt B; Brugieres L;
J Med Genet; 2014 Jun; 51(6):355-65. PubMed ID: 24737826
[TBL] [Abstract] [Full Text] [Related]
15. [Constitutional mismatch repair-deficiency syndrome (CMMR-D) - a case report of a family with biallelic MSH6 mutation].
Ilenčíková D
Klin Onkol; 2012; 25 Suppl():S34-8. PubMed ID: 22920205
[TBL] [Abstract] [Full Text] [Related]
16. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
[TBL] [Abstract] [Full Text] [Related]
17. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
[TBL] [Abstract] [Full Text] [Related]
18. 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
Paulitschke V; Schicher N; Szekeres T; Jäger W; Elbling L; Riemer AB; Scheiner O; Trimurtulu G; Venkateswarlu S; Mikula M; Swoboda A; Fiebiger E; Gerner C; Pehamberger H; Kunstfeld R
J Invest Dermatol; 2010 Jun; 130(6):1668-79. PubMed ID: 19956188
[TBL] [Abstract] [Full Text] [Related]
19. Expression of DNA mismatch repair proteins and msh2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients.
Perrett CM; Harwood CA; McGregor JM; Warwick J; Cerio R; Karran P
Br J Dermatol; 2010 Apr; 162(4):732-42. PubMed ID: 19818066
[TBL] [Abstract] [Full Text] [Related]
20. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Boeckmann L; Schirmer M; Rosenberger A; Struever D; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Schoen MP; Brockmoeller J; Emmert S
Pharmacogenet Genomics; 2009 Oct; 19(10):760-9. PubMed ID: 19741564
[TBL] [Abstract] [Full Text] [Related]
[Next]
